Satsuma Pharmaceuticals to Release Earnings on Friday

STSADelisted Stock  USD 1.10  0.01  0.90%   
About 61% of Satsuma Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Satsuma Pharmaceuticals suggests that many traders are alarmed regarding Satsuma Pharmaceuticals' prospects. The current market sentiment, together with Satsuma Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Satsuma Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Satsuma Pharmaceuticals is set to post its quarterly earnings results on Friday, March 17th. Satsuma Pharmaceuticals Trading Up 4.0 percent NASDAQ STSA traded up 0.04 on Thursday, hitting 0.91. 40,884 shares of the companys stock were exchanged, compared to its average volume of 142,725. The stock has a 50-day moving average

Read at thelincolnianonline.com
news
  

Satsuma Pharmaceuticals Fundamental Analysis

We analyze Satsuma Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Satsuma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Satsuma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Asset

Return On Asset Comparative Analysis

Satsuma Pharmaceuticals is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Satsuma Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Satsuma Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Satsuma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Satsuma Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Satsuma Pharmaceuticals Related Equities

FBRXForte Biosciences   11.27   
0%
100.0%
LRMRLarimar Therapeutics   8.79   
0%
77.0%
CYCNCyclerion Therapeutics   5.59   
0%
49.0%
KRONKronos Bio   4.12   
0%
36.0%
PMVPPmv Pharmaceuticals   3.92   
0%
34.0%
ASMBAssembly Biosciences   3.91   
0%
34.0%
ACHLAchilles Therapeutics   2.63   
0%
23.0%
SNTISenti Biosciences   2.36   
0%
20.0%
MNOVMediciNova   1.43   
0%
12.0%
PEPGPepGen   1.32   
0%
11.0%
ERASErasca   0.74   
0%
6.0%
ADXNAddex Therapeutics   0.00   
0%
0%
CTMXCytomX Therapeutics   0.00   
0%
0%
CINGCingulate   1.01   
8.0%
0%
PHVSPharvaris   1.24   
11.0%
0%
TILInstil Bio   1.39   
12.0%
0%
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Satsuma Stock

If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine